Evofem Biosciences to Report Third Quarter 2020 Results and Provide Corporate Update on Monday, November 9, 2020
10/27/2020 - 08:00 AM
SAN DIEGO , Oct. 27, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) will hold a webcast and conference call to discuss the Company's financial results and business highlights for the third quarter ended September 30, 2020 as follows:
Date
Monday, November 9, 2020
Time
5:00 p.m. ET (2:00 p.m. PT)
Webcast (live and archived)
www.evofem.com under "Investors "
Dial-in numbers
(866) 503-5561 (U.S. toll-free) or (253) 336-2965
Conference ID
2639368
The live webcast and related slide presentation can be accessed on the Company's Investor page at https://evofem.investorroom.com/events or directly at https://edge.media-server.com/mmc/p/e4ij5fy8 . Please connect to the Company's website at least 15 minutes prior to the start of the call to download any software that may be required.
If participating by phone, please dial in approximately 15 minutes prior to the start of the call.
A telephone replay will be available approximately two hours after the call through Thursday, November 12, 2020 at (855) 859-2056 (U.S.) or (404) 537-3406 (International), conference ID 2639368. The webcast will be archived at https://evofem.investorroom.com/events .
About Evofem Biosciences, Inc.
Evofem Biosciences, Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company's first commercial product, Phexxi™ (lactic acid, citric acid and potassium bitartrate) , is the first and only hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. The Company is evaluating EVO100 in a Phase 3 clinical trial, 'EVOGUARD ,' for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. For more information, please visit www.evofem.com .
Phexxi™ is a trademark of Evofem Biosciences, Inc.
Investor Relations Contact Amy Raskopf Evofem Biosciences, Inc.araskopf@evofem.com Mobile: (917) 673-5775
Media Contact Ellen Thomas Evofem Biosciences, Inc.ethomas@evofem.com Mobile: (718) 490-3248
View original content to download multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-to-report-third-quarter-2020-results-and-provide-corporate-update-on-monday-november-9-2020-301160339.html
SOURCE Evofem Biosciences, Inc.
EVFM Rankings
N/A Ranked by Stock Gains
EVFM Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
San Diego
About EVFM
evofem is a biotechnology company focusing on developing innovative reproductive health products for women in every global market. evofem develops and markets products that are woman-controlled, non-invasive and rapidly reversible. women need access to effective products that are well suited to their lifestyle and consistent with their core values. products include: amphora™ - a non-hormonal vaginal gel being investigated for contraceptive and microbicidal properties.